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Background: Symptom burden in chronic kidney disease (CKD) is poorly understood. To date, the majority of
research focuses on single symptoms and there is a lack of suitable multidimensional symptom measures. The
purpose of this study was to modify, translate, cross-culturally adapt and psychometrically analyse the Dialysis
Symptom Index (DSI).
Methods: The study methods involved four phases: modification, translation, pilot-testing with a bilingual non-CKD
sample and then psychometric testing with the target population. Content validity was assessed using an expert
panel. Inter-rater agreement, test-retest reliability and Cronbach’s alpha coefficient were calculated to demonstrate
reliability of the modified DSI. Discriminative and convergent validity were assessed to demonstrate construct validity.
Results: Content validity index during translation was 0.98. In the pilot study with 25 bilingual students a moderate to
perfect agreement (Kappa statistic = 0.60-1.00) was found between English and Arabic versions of the modified DSI.
The main study recruited 433 patients CKD with stages 4 and 5. The modified DSI was able to discriminate between
non-dialysis and dialysis groups (p < 0.001) and demonstrated convergent validity with domains of the Kidney
Disease Quality of Life short form. Excellent test-retest and internal consistency (Cronbach’s α = 0.91) reliability
were also demonstrated.
Conclusion: The Arabic version of the modified DSI demonstrated good psychometric properties, measures
the multidimensional nature of symptoms and can be used to assess symptom burden at different stages of
CKD. The modified instrument, renamed the CKD Symptom Burden Index (CKD-SBI), should encourage greater
clinical and research attention to symptom burden in CKD.
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Chronic kidney disease (CKD) is associated with a wide
range of physical and psychological symptoms which have
a negative impact on health-related quality of life [1]. Fa-
tigue, pain, pruritus, sleep disturbances and decreased ap-
petite are some of the most prevalent and frequently
reported symptoms in CKD patients [2] and are the main
predictors of increased morbidity and mortality [3,4]. Alle-
viating or controlling symptoms in CKD patients are one
of the main priorities of the renal multidisciplinary team* Correspondence: hayfa.almutary@connect.qut.edu.au
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unless otherwise stated.and thus require comprehensive assessment [5]. A major
impediment to understanding the symptom experience in
CKD is the lack of suitable measures that examine a wide
range of symptoms across key dimensions (i.e. prevalence,
severity, frequency and distress). Symptom prevalence
alone does not reflect the complete patient symptom ex-
perience. The symptom experience is much better under-
stood in cancer patients as a multidimensional burden
comprising prevalence, distress, severity and frequency
[6,7]. Though CKD patients often have greater prevalence
and distress than advanced cancer patients [2], severity
and frequency are rarely measured.
The Dialysis Symptom Index (DSI) is the most frequently
used measure to assess symptoms in CKD and end stageal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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DSI was designed to examine the prevalence and distress
of 30 self-reported physical and emotional symptoms. This
contrasts with the purposes of other available instruments,
such as the Modified Edmonton Symptom Assessment
System [9], the Patient Outcome Scale Symptom Module
(POS-S) [10] and the Pittsburgh Symptom Score [11]
that have been used to assess symptom burden in CKD
patients. However, none of the currently available in-
struments measure the multidimensional nature of
symptoms [12,13].
The ideal CKD symptom assessment measure should
assess a range of symptoms and be able to determine the
prevalence, distress, severity and frequency of symptoms
[2]. The purpose of this study was to modify, translate,
culturally adapt, and then evaluate the psychometric
properties of the Arabic version of the DSI. It was part
of a larger study examining symptom clusters in people
with CKD.
Methods
The psychometric property testing involved four phases:
modification of the DSI, translation, pilot study and the
main study.
Phase 1 - Instrument modification
Permission was granted by Weisbord to modify and then
translate the DSI into Arabic. First, two symptoms (de-
pression and nocturia) and three free fields were added.
Both depression [14] and nocturia [15,16] are highly
prevalent in CKD, but are not routinely included in symp-
tom measures. The additional free fields were included to
capture any possible symptoms that were missing from
the DSI. Then two symptom dimensions (severity and fre-
quency) were also added to the DSI [2,12,13]. All symp-
tom dimensions (frequency, severity and distress) were
rated on a 0-10 point scale because this type of response
scale is easier for patients to use (i.e. similar to the com-
monly used numerical pain rating scale), provides a wider
range of possible scores, and increases the statistical ana-
lyses that are available. In the original DSI, patients were
asked to consider symptoms they had experienced in the
previous week. However, we extended the time frame to
four weeks to reflect the chronic nature of CKD symp-
toms. For example, some symptoms may occur often only
during dialysis (e.g. cramps and dizziness) and may not
be persistent over 4 weeks. These modifications cre-
ated a comprehensive instrument, re-named (with per-
mission from Weisbord) the CKD Symptom Burden
Index (CKD-SBI), to assess symptoms in different stages
of CKD. The time needed to complete the modified in-
strument ranged between 15 to 30 minutes.
The CKD-SBI includes four symptom dimensions
(prevalence, distress, severity and frequency) across 32symptoms (see Additional file 1). The prevalence scale
assesses the presence or absence (Yes/No) of each symp-
tom with a higher overall score indicating a higher symp-
tom occurrence. The possible range of prevalence scores
is 0-32. Distress, severity and frequency are each measured
using a 0 to 10 scale for each of the symptoms. Partici-
pants rate the “distress” subscale from none to very much,
“severity” from none to very severe, and “frequency” from
never to constant. A maximum total score for each of
these scales is 320 (range 0-320). The total CKD-SBI score
is calculated by summing the scores of each CKD-SBI sub-
scale (prevalence, distress, severity and frequency) and
then multiplying the result by 0.1008 (constant number).
The total score for the CKD-SBI scale therefore ranges be-
tween 0-100, where 100 indicates the highest symptom
burden possible.
Phase 2 - Translation procedure
We used the Brislin back-translation method [14,17]; the
most frequently used and accepted method for effective
translation equivalence of instruments [18]. The method
begins with a bilingual expert translating the instrument
from its source language (English) into the target language
(Arabic). Consultations with an expert panel are an im-
portant stage to ensure clarity, detect linguistic mistakes
and ensure cross-cultural equivalence [19]. Then a blind
back-translation (without accessing the original source lan-
guage version) from the target language to the source lan-
guage should be undertaken by another bilingual translator
[18]. The back-translated version is then compared with
the original version. If there are errors in the meaning in
the blind back-translated version after comparison with
the original version, the process of translation is repeated
for the sections that include errors in the meaning [20].
Figure 1 summarises the steps in the Brislin’s method.
Translation processes were undertaken in Saudi Arabia
using bilingual (Arabic/ English), certified translators. For-
mal written Arabic language was used as this form of
Arabic is used in all Arabic-speaking countries; thus in-
creasing the usefulness of the instrument to other CKD
populations outside of Saudi Arabia. The Arabic expert
panel involved three nephrology nurses, two nephrolo-
gists, a social worker and two primary school teachers.
The goal of the panel was to: 1) ensure clarity, readability
and linguistic appropriateness; 2) review of grammatical
style and comprehensibility; and 3) maintain cultural
equivalence. The primary school teachers ensured suit-
able literacy level of the CKD-SBI for people with limited
literacy skills (which will be tested in the pilot study). The
expert panel recommended several minor linguistic and
grammatical modifications, correction of spelling, and
clearer instruction statements. A blind back-translation
from the Arabic version into English was then performed
by another bilingual certified translator independently
Errors 
identified  
(Step 1) 
Forward translate SL version to the TL version 
(Step 3) 
Blind back-translation 
(Step 2) 
Consultation of expert panel  
 (Step 4) 
Compare the SL version and back-translated 
version for linguistic and cultural equivalence No errors identified,  
Pilot study
Figure 1 Steps of Brislin’s method of translation application.
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English CKD-SBI. The procedure that was used to com-
pare the back-translated version with the original version
involved a new independent professional translator, two
bilingual members of the expert panel and the first author.
There were no errors identified in meaning after compar-
ing both versions.
Content validity index (CVI) testing also occurred dur-
ing this phase using the expert panel and a professional
translator from a Saudi hospital. Individually they were
asked to rate their level of agreement with the relevance
and equivalence of each item between the Arabic and
English versions on a four-point scale (1 = ‘not relevant’
to 4 = ‘very relevant’) to evaluate content validity [21]. A
score of 3 or 4 indicates that the translated item is valid
and equivalent to the English version [21]. The total CVI
was 0.98 with items ranging from 0.88-1.00, which indi-
cated that the CKD-SBI had good content validity.
Phase 3 - Pilot study
Siaki [22] recommends pretesting of a translated instru-
ment as a method to determine equivalence between the
target language and source language. We conducted a
pilot study of both versions of the CKD-SBI using bilin-
gual university students and measured test-retest reli-
ability, intra-rater reliability and internal consistency. As
symptoms are also experienced by normal healthy popu-
lations but in a lesser frequency than those with CKD,
using university students was appropriate when assessing
language equivalence. Several studies have used this
method when assessing language equivalence [23-25]. The
pilot study involved anonymous completion of the English
and Arabic versions of the CKD-SBI, on two separate
occasions, one week apart. Demographic information(i.e. age, gender) was not relevant to determining equiva-
lence and was not collected. An Arabic announcement
was applied to the university notice board, and a snowball
sampling technique was used to recruit participants dur-
ing April-May, 2013. Ethics approval was obtained from
the Queensland University of Technology (QUT) prior to
commencement.
Phase 4 - Main study
The main study used a cross-sectional design to evaluate
the psychometric properties of the CKD-SBI in Arabic-
speaking CKD patients who were either receiving dialysis
or not. A convenience sample of CKD patients from three
hospitals in Saudi Arabia were recruited during July 2013
to February 2014. Initially treating clinicians identified po-
tential eligible participants - adults with CKD (eGFR < 30
mls/min/1.73 m2) or currently receiving either haemodi-
alysis or peritoneal dialysis, willing to participate, and able
to communicate in Arabic. Exclusion criteria were cog-
nitive impairment that would preclude voluntary, in-
formed consent, and those with critical conditions. Ethical
approval was obtained from King Abdulaziz University
Hospital, Jeddah Research Centre, and QUT Human
Research Ethics Committees. All participants provided
written informed consent. Data was collected through
in-person distribution in the nephrology clinics (non-dia-
lysis CKD patients) and the kidney dialysis centres (dialy-
sis patients). Participants completed the newly translated
Arabic version of the CKD-SBI (32 items) along with the
Kidney Disease Quality of Life short form (KDQOL-36™).
The KDQOL-36™ has 36 items and is available in Arabic
[26]. The total score of the KDQOL-36 ranges from
0-100, with higher scores indicating a better QOL.
Demographic and renal characteristics were also collected.
Table 1 Percentage of equivalence and Kappa statistics
for English and Arabic CKD Symptom Burden Index for
the pilot study (N = 25)
Symptom % of
agreement
K (p)
1. Constipation 92 0.841 (<0.001)
2. Nausea 100 1.00 (<0.001)
3. Vomiting 96 0.896 (<0.001)
4. Diarrhoea 100 1.00 (<0.001)
5. Decreased appetite 100 1.00 (<0.001)
6. Muscle cramps 100 1.00 (<0.001)
7. Swelling in legs 100 1.00 (<0.001)
8. Shortness of breath 100 1.00 (<0.001)
9. Light headedness or dizziness 100 1.00 (<0.001)
10. Restless legs or difficulty keeping
your legs still
96 0.834 (<0.001)
11. Numbness or tingling in feet 100 1.00 (<0.001)
12. Feeling tired or lack of energy 100 1.00 (<0.001)
13. Cough 100 1.00 (<0.001)
14. Dry mouth 100 1.00 (<0.001)
15. Bone or joint pain 100 1.00 (<0.001)
16. Chest pain 100 1.00 (<0.001)
17. Headache 96 0.779 (<0.001)
18. Muscle soreness 100 1.00 (<0.001)
19. Difficulty concentrating 100 1.00 (<0.001)
20. Dry skin 100 1.00 (<0.001)
21. Itching 100 1.00 (<0.001)
22. Worrying 96 0.803 (<0.001)
23. Feeling nervous 96 0.826 (<0.001)
24. Trouble falling asleep 92 0.828 (<0.001)
25. Trouble staying asleep 100 1.00 (<0.001)
26. Feeling irritable 100 1.00 (<0.001)
27. Feeling sad 100 1.00 (<0.001)
28. Feeling anxious 88 0.603 (0.001)
29. Depression 100 1.00 (<0.001)
30. Decreased interest in sex 100 1.00 (<0.001)
31. Difficulty becoming sexually aroused 100 1.00 (<0.001)
32. Nocturia 100 1.00 (<0.001)
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mate the number of co-morbidities for the sample. This
index consists of seven domains of co-morbid conditions,
including malignancy (active, non-cutaneous); ischaemic
heart disease, peripheral vascular disease, left ventricular
dysfunction, diabetes mellitus (type 1 or 2); systemic colla-
gen vascular disease; or other significant pathology. The
total score is determined by summing the score of each
co-morbid domain. The scores are then graded into three
risk groups: grade 0 is a zero score, grade 1 (1-2 domains),
or grade 2 (3-7 domains).
Statistical analysis
Data for the pilot study and the main study were entered
into IBM SPSS Statistics version 21 in two different data
sets and reported in the results section separately. For
the pilot study, the percentage of agreement between the
original English and Arabic versions of the CKD-SBI was
calculated to examine equivalence. Kappa statistics were
used to assess the inter-rater agreement between the
English and Arabic versions for categorical data. Intra
Class Correlation coefficient and Wilcoxon signed-ranks
test for matched pairs (numerical scales) were used to
determine the consistency of CKD-SBI scores. The ICC
coefficient was used to estimate the inter-rater reliability
of the CKD-SBI. Pearson’s correlation coefficients were also
calculated to assess the test-retest reliability. Cronbach’s
alpha reliability coefficients were calculated to determine
the internal consistency.
For the main study, descriptive statistics were used to
summarise sample characteristics. Cronbach’s alpha reli-
ability coefficients were calculated to determine the in-
ternal consistency of the CKD-SBI. Pearson’s correlations
were also used to examine associations between symptom
dimensions. Discriminative validity was assessed using
Welch t-tests to assess if the CKD-SBI was able to discern
between known groups according to disease severity
within the CKD population. For convergent validity,
Pearson correlation coefficients were used to examine
the relationships between the symptom subscales of
the CKD-SBI and all domains of KDQOL-36™. Signifi-
cance was set at p < 0.05.
Results
Pilot study
The pilot study involved 25 bilingual students, produ-
cing 25 matched English (E)/Arabic (A) pairs. There was
a high percentage of agreement between E and A versions
across all the items with a mean of 98.45 ± 3.04 (range =
88-100%). Level of agreement between the E and A ver-
sions revealed Kappa (κ) scores ranging from 0.603 – 1.0.
The strength of agreement is considered poor when κ <
0.20, fair between 0.21 and 0.40, moderate between 0.41
and 0.60, substantial between 0.61 and 0.80, and excellentwhen κ > 0.80 [28]. Most items (23 out of 31) revealed a κ
of 1.00 indicating complete agreement (see Table 1). The
ICC score indicated an excellent agreement between the E
and A versions of the CKD-SBI (ICC = 0.99, p < 0.001). In
addition, the Wilcoxon signed rank test was used to exam-
ine the difference between the E and A versions for the
total CKD-SBI scale and for each subscale (prevalence,
distress, severity and frequency). The results revealed no
significant differences between the E and A versions of the
CKD-SBI for the total scale of CKD-SBI (Z = 1.79, p =
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p = 0.18), distress (Z = 1.14, p = 0.26), severity (Z = 1.83,
p = 0.68) and frequency (Z = 1.48, p = 0.14).
Pearson’s correlation coefficients assessed test-retest
reliability and revealed a strong positive correlation be-
tween the mean scores for both versions of the CKD-SBI
(r = 0.997, p < 0.01). A Cronbach’s alpha coefficient of 0.7 is
generally accepted to estimate the internal consistency of a
new scale [29]. Cronbach’s alpha coefficients for the E ver-
sion (Cronbach’s α = 0.897) and the A version (Cronbach’s
α = 0.899) both demonstrated good internal consistency.
Main study
Sample characteristics
A total of 433 patients with CKD were recruited. The
mean age was 48.23 ± 14.89 years, 52.9% were male, and
58.4% had at least one co-morbid condition. Most of the
participants were receiving dialysis treatment (n = 329,
76%). Diabetes and hypertension were the leading causes
of CKD in our sample. The overall mean of KDQOL-36
score was 58.08 ± 20.04, ranging from 6.88 to 99. Sample
characteristics are summarised in Table 2.
CKD-SBI psychometric results
The total mean CKD-SBI score was 17.98 ± 16.11, ranging
from 0 to 83.36. Symptoms were highly prevalent in this
sample of CKD patients (mean = 12.58 ± 7.9; range 0-32).Table 2 Sample characteristics for the main study (N = 433)
Characteristics n %
Age (mean, SD) 48.23 14.89
Gender
Male 229 52.9
Female 204 47.1
Marital status
Married 257 59.4
Not married 175 40.4
Treatment type
Dialysis 329 76
Non-dialysis (eGFR 5-29 mL/min/1.73 m2) 104 24
Causes of CKD
Diabetic nephropathy 135 31.2
Hypertensive nephropathy 146 33.7
Primary glomerular disease 30 6.9
Unknown aetiology 59 13.6
Others 63 14.5
Comorbid conditions
0 180 41.6
1-2 223 51.5
≤3 30 6.9
Percentages vary depending on missing data.As the purpose of this article is to present the psycho-
metric analysis of the CKD-SBI further descriptive re-
sults are not required and will be presented in another
separate paper. Summary statistics for each subscale of
CKD-SBI are presented in Table 3. There was a high in-
ternal consistency of the overall CKD-SBI (Cronbach’s α =
0.91) and subscales (range = 0.93 - 0.90). There were strong
positive intercorrelations between CKD-SBI subscales,
which ranged from 0.82 - 0.97 (see Table 3).
Discriminative validity
Discriminative validity is the ability of an instrument to dis-
tinguish between groups that are expected to differ based
on their clinical diagnosis or other characteristics [30]. It is
an important measure of construct validity, which is com-
monly examined through the “known groups” technique
[30]. As renal function deteriorates, symptoms become
more prevalent due to the accumulation of uraemic toxins
[31]. Thus we divided the sample into two groups (dialysis
and non-dialysis patients) and compared the total symp-
tom burden score. We hypothesised that symptom burden
would increase as GFR decreases. Due to the unequal
sample size, Welch t-tests were used to compare groups
[32]. This showed significant differences in total symptom
burden scores (t (403.5) = -13.1, p < 0.001), indicating that
the CKD-SBI is able to discriminate between groups that
have different eGFR levels.
Convergent validity
Convergent validity refers to the degree to which scores
on a measure associate with scores on other measures
that are intended to assess similar constructs [33]. Previ-
ous studies have shown that symptoms among CKD pa-
tients are correlated with poor health-related quality of
life [34,35]. Therefore, we hypothesised that all symptom
dimension scores would be negatively correlated with
domain scores of the KDQOL-36. Pearson’s correlation
coefficients demonstrated moderate to strong relation-
ships in the expected direction between all symptom di-
mensions (prevalence, distress, severity and frequency)
and each domain of the KDQOL-36 (see Table 4).
Discussion
This study modified, translated, culturally adapted and
psychometrically evaluated the CKD-SBI. Jablonski [12]
argues that when examining CKD symptom burden, the
multidimensional nature of symptoms should be consid-
ered. However, a significant criticism of research in this
area is the lack of comprehensive CKD symptom measures.
The DSI was selected as a target instrument in this study
for two reasons. First, there is no disease-specific instru-
ment in Arabic for assessing CKD symptoms. Second, we
believed that the DSI is the best available instrument for
symptom assessment but it required some modifications to
Table 3 Descriptive statistics, reliability and Pearson’s correlation coefficient of the CKD-SBI subscales
Subscale Mean SD Range α 1 2 3 4 5
1. Prevalence 12.58 7.89 0-32 0.924 -
2. Distress 55.47 51.74 0-259 0.904 0.817 -
3. Severity 57.56 52.26 0-265 0.924 0.835 0.963 -
4. Frequency 58.76 50.48 0-273 0.929 0.838 0.943 0.967 -
5. Total symptom burden 17.84 15.98 0-83 0.91 0.857 0.981 0.991 0.983 -
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pects of symptoms and gain better understanding of symp-
tom burden.
The results demonstrated that the CKD-SBI was lin-
guistically and culturally relevant to CKD patients from
Arabic-speaking backgrounds. In the translation process,
no statements required adjustment to fit into the Arabic
cultural context. Excellent content validity of the Arabic
version of the CKD-SBI was demonstrated. Since formal
written Arabic language is universally understood amongst
Arabic speaking nations, this instrument is applicable for
other populations. The DSI was originally developed and
validated for patients receiving dialysis treatment. After
modification, testing and with approval from the DSI ori-
ginator, we renamed the DSI as the CKD Symptom Burden
Index (CKD-SBI), to reflect the utility of the instrument to
measure symptom burden and to broaden its appeal to
other researchers to assess symptoms in the non-dialysis
CKD populations.
In this study, symptoms were highly prevalent among
CKD patients with an average of 12.58 symptoms per pa-
tient. This finding is consistent with a recent comprehen-
sive review of 19 studies, which found the mean symptom
per patients ranged between 6-20 symptoms [2]. Based on
literature, symptoms in CKD were often described as a
part of KDQOL [2]. However, the KDQOL does not meas-
ure the most prevalent symptoms reported in the litera-
ture; that is fatigue, bone or joint pain, and psychological
symptoms. This suggests that using the symptom list of
the KDQOL is not sufficient measure symptom burden in
CKD patients. The results from this study emphasiseTable 4 Pearson correlations between CKD-SBI symptom dim
CKD-SBI KDQOL-36
Total KDQOL
scale score
Physical function
summary
Mental h
summar
Prevalence r = -0.58** r = -0.51** r = -0.41*
Distress r = -0.63** r = -0.51** r = -0.44*
Severity r = -0.61** r = -0.49** r = -0.43*
Frequency r = -0.61** r = -0.51** r = -0.44*
Total symptom burden r = -0.63** r = -0.52** r = -0.44*
*The results are presented after reverse scoring the symptoms and problems subsc
scoring system.
**Correlation is significant at the 0.01 level (2-tailed).using a comprehensive symptom measure to examine
symptom burden among CKD patients.
Overall the results provide initial evidence of validity
and reliability of the CKD-SBI, which has potential clinical
and research implications. One of the strengths of the
main study was having a large sample size and recruiting
CKD patients from three different hospitals. Sample char-
acteristics in this study were similar to population data re-
ported by the Saudi Center for Organ Transplantation
[36] and a recent review on CKD in Saudi Arabia [37],
which provides some evidence that participants were rep-
resentative of the target population. We also administered
the scale to patients with different treatment modalities
and stages of CKD. Good discriminant validity was dem-
onstrated, indicating that the CKD-SBI can discriminate
between patients in stages 4 and 5. A consistent technique
(in-person distribution by one person [first author]) was
used to administer the instrument. This technique assisted
with providing insight into the clinical utility of the instru-
ment. Patients reported acceptability and clarity of the
instrument regardless of age and educational level. The
time taken to complete it was short (on average 20 minutes)
although this was dependent on the number of symp-
toms experienced.
Further evidence of construct validity was demonstrated
by examining relationships between the CKD-SBI and do-
mains of KDQOL-36. These results are consistent with
previous studies that have demonstrated CKD symptoms
are negatively correlated with KDQOL [9,13,35]. Similarly,
Abdel-kader et al. [34] found moderate correlation be-
tween the DSI and Physical Component Summary andension subscales and KDQOL-36 domains (N = 433)
ealth
y
Effects of kidney
disease on daily life
Symptoms and
problems subscale*
Burden of
the disease
* r = -0.47** r = 0.72** r = -0.33**
* r = -0.54** r = 0.78** r = -0.36**
* r = -0.51** r = 0.77** r = -0.34**
* r = -0.49** r = 0.75** r = -0.35**
* r = -0.53** r = 0.75** r = -0.44**
ale of the KDQOL-36 to be consistent and in the same direction with our
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mains using the Medical Outcomes Study Short Form-36.
The results suggest that the two instruments, CKD-SBI
and KDQOL-36, together demonstrated convergent valid-
ity. Used together, they provide clinicians with a compre-
hensive understanding of CKD symptom burden and
relationship with quality of life. The additional informa-
tion gained from this new multidimensional instrument is
better to predict the important patient outcomes such as
HRQoL, depression, morbidity, mortality, which is worth
the additional respondent burden. However, further work
is needed to demonstrate the strong relationships be-
tween symptom burden and other important measures of
HRQOL, depression, morbidity, and mortality.
Limitations
The results are significant as this is the first study to valid-
ate a comprehensive instrument designed to assess CKD
symptom burden. However, there are several limitations
that should be acknowledged. It is difficult to identify bi-
lingual patients thus test-retest agreement may have been
overestimated by use of the instrument in a generally
healthy population (university students). Also, the test-
retest reliability was one week apart, thus there was poten-
tial for stability bias as participants could have memorised
their responses between the two tests [30]. Since this
instrument has been validated only in Arabic-speaking
people with CKD stage 4 and 5, more research is needed
to validate this instrument in English-speaking popula-
tions as well as in other CKD stages. In addition, it would
have been ideal to compare the CKD-SBI with another
multidimensional symptom measure, but another suitable
instrument is not yet available. This limits the establish-
ment of criterion-related validity for the CKD-SBI.
Conclusion
The CKD-SBI demonstrated good psychometric proper-
ties and is suitable to assess symptom burden for different
CKD populations. It is comprehensive and can capture the
multidimensional aspects of a range of symptoms. Asses-
sing symptom burden could help health professionals to
have a better understanding of the symptom experience of
CKD patients and to identify symptoms that have a major
impact on health-related quality of life. The lack of know-
ledge of the symptom experience and its impact on peo-
ple’s lives leads to under-assessment and treatment of
symptoms. This new multidimensional instrument should
encourage greater clinical and research attention to symp-
tom burden in CKD.Additional file
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